Novo Nordisk has entered a license agreement with Omeros for the development and commercialization of zaltenibart (OMS906), an…
Articles by Andrea Lobo, PhD
Ultomiris (ravulizumab-cwvz) is as effective or better than Soliris (eculizumab) at keeping paroxysmal nocturnal hemoglobinuria (PNH) under control,…
Treatment with HRS-5965, a complement inhibitor being developed by Jiangsu Hengrui Pharmaceuticals, increased the levels of hemoglobin and reduced…
A teenage girl with paroxysmal nocturnal hemoglobinuria (PNH) who experienced extravascular hemolysis, which occurs when red blood cells are…
Six months of Fabhalta (iptacopan) raised hemoglobin levels, eliminated the need for blood transfusions, and eased fatigue in most…
Close monitoring and Empaveli (pegcetacoplan) dose adjustments before and after surgery effectively prevented episodes of breakthrough hemolysis,in a 67-year-old…
Clinical site activation is now ongoing for a Phase 3 program that will evaluate zaltenibart (OMS906) as a treatment for…
An unusual meningococcal infection during treatment with Empaveli (pegcetacoplan) was reported in a 16-year-old girl with paroxysmal nocturnal…
Note: This story was updated Dec. 6, 2024, to correct that Voydeya is approved as an add-on treatment to standard…
Treatment with Empaveli (pegcetacoplan), approved for adults with paroxysmal nocturnal hemoglobinuria (PNH), may lead to clinically meaningful improvements…